Study Summaries
Study summaries are free for everyone to read. Requires registration for free account of GYOEDU
💡
The information provided on this website is intended for general informational purposes only and should not be considered medical advice. While we strive to ensure the content is accurate and up-to-date, Gyoedu LLC does not guarantee the information's correctness, completeness, or timeliness. Users are encouraged to independently verify any information found on this site.
💡
Easy access to all study summaries on your phone and much more!
GYOEDU Study Summary iOS App Released
Shitanshu Uppal
Cervical Cancer
- Early Disease
- GOG 109: Adjuvant ChemoRT After Radical Hysterectomy
- LANDONI Trial
- GOG-71:RT +/- Extrafascial Hysterectomy
- LACC: MIS vs. Open Radical Hysterectomy 2024 (JCO final OS update)
- SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
- CONCERV Trial: Conservative Surgery in Early-Stage Cervical Cancer
- GOG 278: Extra-fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy, for stage IA1, IA2, and IB1 cervical cancer
- GOG 92: Sedlis Criteria Study
- Sentinel Lymph Nodes
- Locally Advanced Disease
- GOG 85: Cisplatin/5-FU Concurrent ChemoRT, Cervix
- GOG 120: Cisplatin ChemoRT in Locally Advanced Cervix
- GOG 123: ChemoRT + Adjuvant Hysterectomy, Bulky IB
- EORTC-55994: Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
- UTERUS-11:Surgical versus clinical staging before primary chemoradiation
- Tata Memorial Hospital Trial: Neoadjuvant Chemo + Rad Hyst Vs. Standard ChemoRT
- OUTBACK Trial: Chemotherapy after Chemoradiation
- KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
- CALLA: Durvalumab versus placebo with chemoradiotherapy
- Interlace Trial: Induction Chemotherapy prior to Chemoradition for Locally Advanced Cervical Cancer
- Recurrent/Metastatic Disease
- GOG 240: Bevacizumab in Cervical Cancer
- Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial
- Tisotumab in Cervical Cancer: InnovaTV 301/ENGOT-cx12/GOG-3057 Phase 3 trial
- Immunotherapy Trials
- BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
- KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- COMPASSION 16: Cadonilimab for persistent, recurrent, or metastatic cervical cancer
- CHECKMATE 0358-Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer
- Camrelizumab and Famitinib in Cervical Cancer - Phase II
- RTOG 90-01 (Morris): Concurrent Chemoradiotherapy vs Extended-Field Radiation in Locally Advanced Cervical Cancer
- EMPOWER-Cervical 1: Cemiplimab vs Chemotherapy in Recurrent/Metastatic Cervical Cancer
Endometrial Cancer
- Surgical Trials
- High-Risk
- PORTEC 1: EBRT vs. Observation in Endometrial Cancer
- GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
- PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
- Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer
- Advanced/Recurrent Disease
- GOG 161: Ifosfamide ± Paclitaxel in Uterine Carcinosarcoma
- Fader: Trastuzumab in HER2+ Uterine Serous Carcinoma
- GOG 122:RT vs. Chemo in Endometrial Cancer
- GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer
- GOG 238: Radiation With or Without Cisplatin in Locally Recurrent Endometrial Cancer
- GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
- PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer
- GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
- NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
- SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer
- Immunotherapy Trials
- Upfront therapy
- Recurrence
- Hormonal/Targeted Therapy Trials
- GOG-99 (Keys): Adjuvant Pelvic Radiation in Intermediate-Risk Endometrial Cancer
- AtTEnd: Atezolizumab plus Chemotherapy for Advanced or Recurrent Endometrial Cancer
- PORTEC-4a: Molecular Profile-Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
- Fulvestrant + Abemaciclib in HR-Positive Advanced or Recurrent Endometrial Cancer
Ovarian Cancer
- Early Stage Disease
- Surgical trials
- LION: Lymphadenectomy in Advanced Ovarian Cancer
- PDS vs. NACT Trials
- Secondary debulking trials
- Upfront treatment trial
- ICON3: Paclitaxel-Carboplatin vs Carboplatin/CAP First-Line
- GOG 182 / ICON5: Five-Arm First-Line Trial
- GOG 111: Cisplatin + Paclitaxel Front-Line
- GOG 158: Carbo/Taxol vs. Cis/Taxol
- MITO-7: Weekly chemotherapy in ovarian cancer
- SCOTROC: Carboplatin and Taxotere in Ovarian Cancer
- Dose-Dense therapy trials
- Intraperitoneal therapy and HIPEC trials
- GOG 172: IP chemotherapy
- GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
- OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- Korean HIPEC trial
- Korean HIPEC trial - IDS only 2023
- CHIPOR Trial: Secondary Debulking and HIPEC in PSOC
- PARP Maintenance Trials
- Study 19: Olaparib Maintenance in Platinum-Sensitive Relapse
- ARIEL3: Rucaparib Maintenance in Recurrence
- NOVA/ENGOT-OV16: Niraparib Maintenance in Recurrence
- VELIA: Veliparib First-Line + Maintenance
- SOLO 1: Olaparib in BRCA mutated patients
- PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- PAOLA-1:Overall Survival Data
- PARPs as Treatment Trials in Recurrence
- Bevacizumab Trials (Upfront)
- Recurrent treatment trials
- Platinum-Sensitive Disease
- Platinum-Resistant Disease
- Bevacizumab Trials (Recurrence)
- Low-Grade Ovarian
- Mucinous Ovarian Cancer
- AURELIA: Bevacizumab plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer
- SOLO2/ENGOT-Ov21: Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Relapse (Final OS)
Vulvar Cancer
- Sentinel Nodes
- Locally Advanced Disease
- GROINSS-V I (van der Zee): Sentinel Node Dissection as Sole Groin Staging in Early-Stage Vulvar Cancer
Sarcoma
- PALETTE study: Pazopanib in Sarcoma
- GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
- GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas
- LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma
Clear Cell Carcinoma
- PEACOCC Phase 2 trial - Pembrolizumab single agent in Recurrent Gynecologic Clear Cell Carcinoma
- LARA Phase 2 trial - Pembrolizumab + Lenvatinib in Recurrent Gynecologic Cancers
Gestational Trophoblastic Neoplasia
- GOG 174: Weekly Methotrexate vs Pulsed Dactinomycin for Low-Risk GTN
- GOG 242: Second Curettage for Low-Risk Nonmetastatic GTN
Old Study Summaries
To access old study summaries submitted by volunteers, click here: